Novo Nordisk A/S
OLIGOMER EXTENDED INSULIN-FC CONJUGATES AND THEIR MEDICAL USE

Last updated:

Abstract:

This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to a novel Fc fragment, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions.

Status:
Application
Type:

Utility

Filling date:

9 Oct 2019

Issue date:

23 Dec 2021